美迪西涨2.03%，成交额2.47亿元，主力资金净流出2540.02万元

Group 1 - The core viewpoint of the articles highlights the recent performance and financial metrics of Medisi, indicating a significant increase in stock price and fluctuations in trading volume [1][2] - As of September 24, Medisi's stock price rose by 2.03% to 69.76 CNY per share, with a total market capitalization of 9.372 billion CNY [1] - Year-to-date, Medisi's stock has increased by 131.22%, with a recent decline of 8.21% over the last five trading days [1] Group 2 - Medisi operates in the pharmaceutical and biotechnology sector, specifically in medical research outsourcing, and is involved in various concept sectors including CRO and AI medicine [2] - For the first half of 2025, Medisi reported a revenue of 540 million CNY, reflecting a year-on-year growth of 3.64%, while the net profit attributable to shareholders was -12.8984 million CNY, showing an increase of 81.63% compared to the previous period [2] - The company has distributed a total of 158 million CNY in dividends since its A-share listing, with 33.9365 million CNY distributed over the past three years [3]